Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 mRNA-transfected autologous dendritic cell vaccination in acute myeloid leukemia
NL-OMON27609Phase 1Active, not recruiting
- Sponsor
- Antwerp University Hospital
- Start
- Mar 2005
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of WT1 mRNA-loaded autologous monocyte-derived dendritic cells in acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts (MDS-EB), sponsored by Antwerp University Hospital. Primary endpoint: Safety of multiple dendritic cell injections. Started Mar 2005; status: active, not recruiting.
02
Drugs
WT1 mRNA-loaded autologous monocyte-derived dendritic cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on NL-OMON27609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27609.